ITPRIPL1: A Potential Drug Target for Psychiatric Disorders (G150771)

Target Name: ITPRIPL1

NCBI ID: G150771

ITPRIPL1

Other Name(s): Inositol 1,4,5-triphosphate receptor interacting protein-like 1 | ITPRIP like 1 | IPIL1_HUMAN | ITPRIPL1 variant 1 | inositol 1,4,5-triphosphate receptor-interacting protein-like 1 | ITPRIP like 1, transcript variant 1 | KIAA1754L | Inositol 1,4,5-trisphosphate receptor-interacting protein-like 1 (isoform 1) | Inositol 1,4,5-triphosphate receptor-interacting protein-like 1 | inositol 1,4,5-trisphosphate receptor interacting protein-like 1 | Inositol 1,4,5-trisphosphate receptor-interacting protein-like 1

ITPRIPL1: A Potential Drug Target for Psychiatric Disorders

ITPRIPL1 (Inositol 1,4,5-triphosphate receptor interacting protein-like 1) is a protein that has been identified as a potential drug target or biomarker for various psychiatric and neurological disorders. It is a member of the ITPR family, which includes several related proteins that play important roles in intracellular signaling pathways. The ITPR family has been implicated in the development and progression of various psychiatric and neurological disorders, including depression, anxiety, and schizophrenia.

The ITPR family is characterized by the presence of a unique N-terminal hypervariable region (HVR), which is capable of interacting with various signaling molecules, including inositol triphosphate (ITP), a critical intracellular signaling molecule. ITP is a key regulator of various cellular processes, including protein synthesis, DNA replication, and cell signaling. It is also involved in the regulation of cell survival and proliferation.

The N-terminal HVR of ITPRIPL1 is a well- conserved region that is involved in the interaction with ITP. It consists of a short amino acid sequence that includes a leucine residue, which is known to be important for the stability and activity of the HVR. The HVR is also known for its role in the regulation of protein kinase (PK) activity, as well as the modulation of cellular signaling pathways.

Research has suggested that ITPRIPL1 may be involved in the development and progression of various psychiatric and neurological disorders, including depression, anxiety, and schizophrenia. Studies have shown that ITPRIPL1 levels are often elevated in individuals with these disorders, and that the activity of ITPRIPL1 has been implicated in the regulation of various cellular processes that are involved in the development of these disorders.

In addition to its potential role in the development of psychiatric and neurological disorders, ITPRIPL1 has also been identified as a potential drug target. Studies have shown that inhibition of ITPRIPL1 can enhance the efficacy of antidepressants and that overexpression of ITPRIPL1 can enhance the negative effects of antipsychotic drugs. These findings suggest that ITPRIPL1 may be an attractive target for the development of new psychiatric and neurological therapies.

Despite the potential for ITPRIPL1 as a drug target, further research is needed to fully understand its role in the regulation of psychiatric and neurological disorders. It is also important to consider the potential implications of ITPRIPL1's involvement in these disorders, as well as the potential for false positives or negatives in diagnostic studies.

Conclusion

ITPRIPL1 is a protein that has been identified as a potential drug target or biomarker for various psychiatric and neurological disorders. Its role in the regulation of intracellular signaling pathways, as well as its potential involvement in the development and progression of these disorders, make it an attractive target for further research. While further studies are needed to fully understand ITPRIPL1's role in these disorders, its potential as a drug target is a promising area of research that may have important implications for the treatment of psychiatric and neurological disorders.

Protein Name: ITPRIP Like 1

The "ITPRIPL1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ITPRIPL1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets